Immunogenicity of a booster dose of a bivalent (Asp614Glyand omicron BA.4/5 variant) self-amplifying mRNAnSARS-CoV-2 booster vaccine versus the BNT162b2 omicronBA.4/5 mRNA vaccine: a randomised phase 3 trialNovember 1, 2024